These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28868942)

  • 1. MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.
    Raess PW; Moore SR; Cascio MJ; Dunlap J; Fan G; Gatter K; Olson SB; Braziel RM
    Leuk Lymphoma; 2018 Jun; 59(6):1391-1398. PubMed ID: 28868942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.
    Kluk MJ; Ho C; Yu H; Chen BJ; Neuberg DS; Dal Cin P; Woda BA; Pinkus GS; Rodig SJ
    Am J Clin Pathol; 2016 Feb; 145(2):166-79. PubMed ID: 26834124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.
    Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA
    J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis.
    Lynnhtun K; Renthawa J; Varikatt W
    Pathology; 2014 Apr; 46(3):211-5. PubMed ID: 24614699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
    Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
    Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of "Double Hit" Lymphomas Using Updated WHO Criteria: Insights From Routine MYC Immunohistochemistry in 272 Consecutive Cases of Aggressive B-Cell Lymphomas.
    Sakr H; Cook JR
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):410-415. PubMed ID: 29629947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.
    Ichikawa K; Aritaka N; Ogura K; Hosone M; Ota Y; Sato E; Komatsu N; Hirano T
    Int J Clin Exp Pathol; 2015; 8(6):7559-64. PubMed ID: 26261669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology.
    Moore EM; Aggarwal N; Surti U; Swerdlow SH
    Am J Surg Pathol; 2017 Sep; 41(9):1155-1166. PubMed ID: 28614202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
    Swerdlow SH
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC/BCL2 double-hit high-grade B-cell lymphoma.
    Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
    Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
    Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
    Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
    Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
    Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA
    Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.
    Menter T; Medani H; Ahmad R; Flora R; Trivedi P; Reid A; Naresh KN
    Br J Haematol; 2017 Nov; 179(4):681-684. PubMed ID: 27447126
    [No Abstract]   [Full Text] [Related]  

  • 19. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
    Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
    Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.
    Miura K; Takahashi H; Nakagawa M; Izu A; Sugitani M; Kurita D; Sakagami M; Ohtake S; Uchino Y; Hojo A; Kodaira H; Yagi M; Kobayashi Y; Iriyama N; Kobayashi S; Kiso S; Hirabayashi Y; Hatta Y; Takei M
    Leuk Lymphoma; 2016; 57(6):1335-41. PubMed ID: 26390147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.